Seminars in Nephrology
Volume 25, Issue 4 , Pages 215-226, July 2005

Clinical Pharmacology of Antihypertensive Therapy

  • Addison A. Taylor

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Addison A. Taylor, MD, PhD, Section on Hypertension and Clinical Pharmacology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
  • ,
  • James L. Pool

Section on Hypertension and Clinical Pharmacology, Department of Medicine, Baylor College of Medicine, Houston, TX.

Adequate control of blood pressure poses challenges for hypertensive patients and their physicians. Success rates of greater than 80% in reducing blood pressure to target values among high-risk hypertensive patients reported by several recent clinical trials argue that effective medications currently are available. Yet, only 34% of hypertensive patients in the United States are at their goal blood pressure according to the most recent national survey. Rational selection of antihypertensive drugs that target both the patient’s blood pressure and comorbid conditions coupled with more frequent use of low-dose drug combinations that have additive efficacy and low adverse-effect profiles could improve significantly US blood pressure control rates and have a positive impact on hypertension-related cardiovascular and renal mortality and morbidity. This article reviews the pharmacokinetic and pharmacodynamic principles that underlie the actions of drugs in each of the classes of antihypertensive agents when used alone and in combination, provides practical pharmacologic information about the drugs most frequently prescribed for treatment of hypertension in the outpatient setting, and summarizes the current data influencing the selection of drugs that might be used most effectively in combination for the majority of hypertensive patients whose blood pressures are not controlled adequately by single-drug therapy.

Keywords:  antihypertensive drugs , angiotensin converting enzyme inhibitors , angiotensin receptor blockers , calcium channel antagonists , beta blockers , diuretics , alpha-1 adrenergic blockers , combination therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0270-9295(05)00031-8

doi:10.1016/j.semnephrol.2005.02.006

Seminars in Nephrology
Volume 25, Issue 4 , Pages 215-226, July 2005